P2RY1 Gene

P2RY1 (Purinergic Receptor P2Y1)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">P2RY1 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>P2RY1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Purinergic Receptor P2Y1</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>19</td>
</tr>
<tr>
<td class="label">Genomic Location</td>
<td>19p13.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>5028</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>181010</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000142203</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P47900</td>
</tr>
<tr>
<td class="label">Gene Family</td>
<td>P2Y receptor family (GPCR)</td>
</tr>
<tr>
<td class="label">Protein Product</td>
<td>P2Y1 receptor, 41 kDa</td>
</tr>
<tr>
<td class="label">Agonist</td>
<td>Affinity (EC50)</td>
</tr>
<tr>
<td class="label">ADP</td>
<td>~1 μM</td>
</tr>
<tr>
<td class="label">ATP</td>
<td>~10 μM</td>
</tr>
<tr>
<td class="label">2-MeSADP</td>
<td>~0.01 μM</td>
</tr>
<tr>
<td class="label">MRS2365</td>
<td>~0.001 μM</td>
</tr>
<tr>
<td class="label">Antagonist</td>
<td>IC50</td>
</tr>
<tr>
<td class="label">MRS2179</td>
<td>~0.4 μM</td>
</tr>
<tr>
<td class="label">MRS2500</td>
<td>~0.01 μM</td>
</tr>
<tr>
<td class="label">Ticagrelor</td>
<

P2RY1 (Purinergic Receptor P2Y1)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">P2RY1 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>P2RY1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Purinergic Receptor P2Y1</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>19</td>
</tr>
<tr>
<td class="label">Genomic Location</td>
<td>19p13.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>5028</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>181010</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000142203</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P47900</td>
</tr>
<tr>
<td class="label">Gene Family</td>
<td>P2Y receptor family (GPCR)</td>
</tr>
<tr>
<td class="label">Protein Product</td>
<td>P2Y1 receptor, 41 kDa</td>
</tr>
<tr>
<td class="label">Agonist</td>
<td>Affinity (EC50)</td>
</tr>
<tr>
<td class="label">ADP</td>
<td>~1 μM</td>
</tr>
<tr>
<td class="label">ATP</td>
<td>~10 μM</td>
</tr>
<tr>
<td class="label">2-MeSADP</td>
<td>~0.01 μM</td>
</tr>
<tr>
<td class="label">MRS2365</td>
<td>~0.001 μM</td>
</tr>
<tr>
<td class="label">Antagonist</td>
<td>IC50</td>
</tr>
<tr>
<td class="label">MRS2179</td>
<td>~0.4 μM</td>
</tr>
<tr>
<td class="label">MRS2500</td>
<td>~0.01 μM</td>
</tr>
<tr>
<td class="label">Ticagrelor</td>
<td>~100 nM</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Type</td>
</tr>
<tr>
<td class="label">MRS2500</td>
<td>Antagonist</td>
</tr>
<tr>
<td class="label">MRS2179</td>
<td>Antagonist</td>
</tr>
<tr>
<td class="label">Ticagrelor</td>
<td>Antagonist</td>
</tr>
<tr>
<td class="label">Brilinta</td>
<td>Approved</td>
</tr>
<tr>
<td class="label">Year</td>
<td>Milestone</td>
</tr>
<tr>
<td class="label">1993</td>
<td>P2Y1 cloning</td>
</tr>
<tr>
<td class="label">1996</td>
<td>Platelet ADP receptor identified</td>
</tr>
<tr>
<td class="label">2000</td>
<td>Brain P2Y1 characterized</td>
</tr>
<tr>
<td class="label">2006</td>
<td>P2Y1 in neuroinflammation</td>
</tr>
<tr>
<td class="label">2011</td>
<td>AD connection</td>
</tr>
<tr>
<td class="label">2015</td>
<td>Stroke research</td>
</tr>
<tr>
<td class="label">2019</td>
<td>PD models</td>
</tr>
<tr>
<td class="label">2022</td>
<td>Therapeutic development</td>
</tr>
<tr>
<td class="label">Species</td>
<td>Agonist Sensitivity</td>
</tr>
<tr>
<td class="label">Human</td>
<td>High</td>
</tr>
<tr>
<td class="label">Mouse</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Rat</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Non-human primate</td>
<td>High</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/covid" style="color:#ef9a9a">Covid</a>, <a href="/wiki/diabetes" style="color:#ef9a9a">Diabetes</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">135 edges</a></td>
</tr>
</table>

Introduction

The P2RY1 gene encodes the P2Y1 receptor, a G protein-coupled receptor (GPCR) that responds to adenine nucleotides, particularly ADP and ATP. P2Y1 is a member of the P2Y receptor family, which plays critical roles in platelet activation, vascular homeostasis, neuroinflammation, and neurodegenerative disease pathogenesis. Originally characterized for its role in platelet aggregation, P2Y1 is now recognized as an important mediator of purinergic signaling in the central nervous system (CNS), where it influences microglial activation, neuronal survival, and inflammatory responses in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders. [@housedick2001]

P2Y1 receptors are widely expressed throughout the brain and immune system, making them attractive therapeutic targets for modulating neuroinflammation. Unlike the P2X7 receptor (which forms ion channels), P2Y1 is a metabotropic receptor that signals through Gq proteins, activating phospholipase C (PLC) and leading to intracellular calcium mobilization. This signaling cascade influences numerous cellular processes relevant to neurodegeneration. [@abbracchio2006]

Gene Overview

Gene Structure

Genomic Architecture

The P2RY1 gene is located on chromosome 19p13.2 and consists of 2 exons spanning approximately 4.5 kilobases. The coding sequence is highly conserved across mammals, reflecting the essential nature of purinergic signaling in platelet function and neural development.

Transcriptional Regulation

P2RY1 expression is regulated by:

Protein Structure and Function

Structural Features

The P2Y1 receptor is a typical class A GPCR with seven transmembrane domains:

Ligand Specificity

Signaling Pathways

P2Y1 signals through Gq/11 proteins:

Normal Function in the Brain

Cellular Expression

P2Y1 receptors are expressed in multiple cell types in the CNS:

Physiological Roles

Purinergic Signaling in the CNS

Extracellular nucleotides (ATP, ADP) serve as danger signals:

• Damage-associated molecular patterns (DAMPs): Released from damaged cells
• Microglial activation: P2Y1 and P2Y12 contribute to activation
• Chemotaxis: Guide microglia to injury sites
• Inflammation modulation: Regulates cytokine production

Role in Alzheimer's Disease

Evidence for P2Y1 Involvement

P2Y1 receptors play complex roles in AD pathogenesis:

Mechanisms of Contribution

• NLRP3 inflammasome activation
• Cytokine release (IL-1β, TNF-α)
• Microglial phagocytosis modulation

• Excitotoxicity
• Mitochondrial dysfunction
• Apoptotic pathways

Therapeutic Implications

P2Y1 as a therapeutic target in AD:

• Antagonists: MRS2500 and derivatives show neuroprotective effects
• Timing: Early intervention may be most effective
• Challenges: BBB penetration, safety margin
• Combination: Targeting multiple P2Y receptors

Role in Parkinson's Disease

Evidence for P2Y1 Involvement

P2Y1 contributes to PD pathogenesis through:

Mechanisms

• Pro-inflammatory cytokine production
• Oxidative stress
• Nitric oxide release

• Calcium dysregulation
• Energy failure
• Apoptotic pathways

Experimental Models

• MPTP model: P2Y1 antagonists protect dopaminergic neurons
• α-Synuclein models: P2Y1 modulation affects pathology
• In vitro: P2Y1 activation promotes microglial neurotoxicity

Role in Stroke and Cerebral Ischemia

Ischemic Injury Response

P2Y1 plays a dual role in cerebral ischemia:

Therapeutic Potential

• P2Y1 antagonists: Show neuroprotection in stroke models
• Timing: Critical window for intervention
• BBB penetration: Required for clinical translation

Role in Neuroinflammation

Microglial Activation

P2Y1 is a key regulator of microglial responses:

Signaling in Inflammation

Cross-talk with Other Receptors

Therapeutic Targeting

Drug Development

Challenges in CNS Drug Development

Novel Approaches

Molecular Interactions

Protein Interactions

Signaling Network

Genetic Associations

P2RY1 Polymorphisms

• rs701265 (Gln323): Associated with platelet reactivity
• rs6808873: Modified stroke risk
• rs10918836: Potential association with AD risk
• Population-specific variants may influence disease susceptibility

Research Timeline

Key Publications

Animal Models

Genetic Models

• P2Y1 knockout mice: Viable with platelet dysfunction
• Conditional knockout: Tissue-specific deletion
• Humanized mice: Improved translation

Disease Models

• APP/PS1 mice: P2Y1 deletion reduces inflammation
• MPTP model: P2Y1 antagonists protect neurons
• Ischemia model: P2Y1 blockade reduces injury

Conclusions

The P2RY1 gene encodes a critical purinergic receptor that bridges platelet function, neuroinflammation, and neurodegenerative disease. While originally characterized for its role in ADP-induced platelet aggregation, P2Y1 is now recognized as an important regulator of microglial activation and neuronal survival in the CNS. Therapeutic targeting of P2Y1 faces challenges related to BBB penetration and peripheral side effects, but novel brain-penetrant antagonists and allosteric modulators offer promise for treating AD, PD, and other neuroinflammatory conditions. Understanding the cell-type-specific functions of P2Y1 and developing selective CNS-acting compounds remains a key research priority.

Brain Region Expression

Hippocampus

The hippocampus shows high P2Y1 receptor expression:

P2Y1 in hippocampus:

• Regulates long-term potentiation (LTP)
• Modulates memory formation
• Affects seizure susceptibility
• Contributes to hippocampal injury responses

Cortex

Cortical P2Y1 expression:

Cortical functions:

• Sensory processing modulation
• Motor control coordination
• Executive function involvement
• Cortical plasticity regulation

Basal Ganglia

P2Y1 in basal ganglia circuits:

Clinical relevance:

• Movement disorder connections
• Parkinson's disease vulnerability
• Dyskinesia development
• Therapeutic targeting potential

Cerebellum

Cerebellar P2RY1 expression:

Functions:

• Motor coordination
• Balance regulation
• Motor learning

Cell Type-Specific Functions

Neuronal P2Y1

Neurons express P2Y1 with distinct functions:

Excitability modulation:

• Depolarization changes
• Action potential threshold
• Firing rate regulation

• Presynaptic modulation of release
• Postsynaptic response modification
• Plasticity mechanisms

• Intracellular calcium regulation
• Mitochondrial calcium handling
• ER calcium release

Astrocytic P2Y1

Astrocyte P2Y1 functions:

Calcium signaling:

• Calcium waves initiation
• Intercellular communication
• Neurovascular coupling

• Lactate release regulation
• Glycogen metabolism
• Energy transfer to neurons

• Reactive astrogliosis modulation
• Scar formation regulation
• Cytokine production

Endothelial P2Y1

Cerebral endothelial P2Y1:

Vascular tone:

• Vasodilation modulation
• Blood flow regulation
• Autoregulation

• Tight junction regulation
• Permeability control
• Leukocyte trafficking

• New vessel formation
• Vessel maintenance
• Repair mechanisms

Oligodendroglial P2RY1

Oligodendrocyte precursor cells (OPCs):

Proliferation: P2Y1 promotes OPC division Differentiation: Influences maturation Migration: Guides cell positioning Myelin maintenance: Protects oligodendrocyte function

Age-Related Changes

Aging and P2Y1

Aging affects P2Y1 expression and function:

Interventions

Modulating P2Y1 in aging:

Comparative Pharmacology

Species Differences

P2Y1 pharmacology varies between species:

Drug Development Implications

Species differences affect:

• Dose selection in clinical trials
• Toxicity predictions
• Efficacy translation
• Therapeutic index determination

Regulatory Considerations

FDA Status

Current P2Y1-targeted drugs:

• Ticagrelor: Approved antiplatelet agent (does not cross BBB)
• P2Y1 antagonists: Preclinical/clinical development
• Combination approaches: Under investigation

Challenges for CNS Drugs

• BBB penetration: Critical barrier
• Peripheral vs. CNS selectivity: Safety profile
• Chronic dosing: Long-term safety
• Biomarker qualification: Patient selection

Future Directions

Research Priorities

Unmet Needs

• Brain-penetrant selective antagonists
• Safe chronic dosing protocols
• Disease-modifying outcomes
• Patient stratification biomarkers

Additional Therapeutic Considerations

Combination Therapies

P2Y1 targeting in combination approaches:

Delivery Systems

Novel approaches under development for CNS targeting:

• Lipid nanoparticles: Engineered lipid carriers for enhanced brain delivery of P2Y1-targeted compounds
• Polymer conjugates: Sustained release formulations for chronic dosing
• Viral vectors: Gene therapy applications using AAV or lentiviral vectors to modulate P2Y1 expression
• Cell-penetrating peptides: Direct CNS delivery through peptide-mediated transport
• Focused ultrasound: Temporary blood-brain barrier opening for enhanced compound delivery

Clinical Development Considerations

See Also

• [P2RY2 Gene](/genes/p2ry2)
• [P2RY12 Gene](/genes/p2ry12)
• [P2RX7 Gene](/genes/p2rx7)
• [Purinergic Signaling](/mechanisms/purinergic-signaling)
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
• [Microglia](/cell-types/microglia)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Platelet Factors in Neurodegeneration](/mechanisms/platelet-factors-neurodegeneration)

Pathway Diagram

The following diagram shows the key molecular relationships involving P2RY1 Gene discovered through SciDEX knowledge graph analysis: